Pharmacoperone drugs: targeting misfolded proteins causing lysosomal storage-, ion channels-, and G protein-coupled receptors-associated conformational disorders

ABSTRACT Introduction: Conformational diseases are caused by structurally abnormal proteins that cannot fold properly and achieve their native conformation. Misfolded proteins frequently originate from genetic mutations that may lead to loss-of-function diseases involving a variety of structurally diverse proteins including enzymes, ion channels, and membrane receptors. Pharmacoperones are small molecules that cross the cell surface plasma membrane and reach their target proteins within the cell, serving as molecular scaffolds to stabilize the native conformation of misfolded or well-folded but destabilized proteins, to prevent their degradation and promote correct trafficking to their functional site of action. Because of their high specificity toward the target protein, pharmacoperones are currently the focus of intense investigation as therapy for several conformational diseases. Areas covered: This review summarizes data on the mechanisms leading to protein misfolding and the use of pharmacoperone drugs as an experimental approach to rescue function of distinct misfolded/misrouted proteins associated with a variety of diseases, such as lysosomal storage diseases, channelopathies, and G protein-coupled receptor misfolding diseases. Expert commentary: The fact that many misfolded proteins may retain function, offers a unique therapeutic opportunity to cure disease by directly correcting misrouting through administering pharmacoperone drugs thereby rescuing function of disease-causing, conformationally abnormal proteins.

[1]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[2]  Joel L Sussman,et al.  Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. , 2007, The Journal of biological chemistry.

[3]  N. Dokholyan,et al.  Protein Destabilization as a Common Factor in Diverse Inherited Disorders , 2015, Journal of Molecular Evolution.

[4]  David Y. Thomas,et al.  Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis. , 2013, Current opinion in chemical biology.

[5]  Ernest Beutler,et al.  Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Ellen Sidransky,et al.  Lysosomal Storage Disorders in the Newborn , 2009, Pediatrics.

[7]  P. Conn,et al.  Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules. , 2016, Current drug targets.

[8]  Guangyu Wu,et al.  Regulation of Anterograde Transport of α2-Adrenergic Receptors by the N Termini at Multiple Intracellular Compartments* , 2006, Journal of Biological Chemistry.

[9]  A. Futerman,et al.  Lysosomal storage disorders: old diseases, present and future challenges. , 2013, Pediatric endocrinology reviews : PER.

[10]  S. Brothers,et al.  'Effective inefficiency': cellular control of protein trafficking as a mechanism of post-translational regulation. , 2006, The Journal of endocrinology.

[11]  Giorgio Colombo,et al.  Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[13]  Emily F. Kirby,et al.  Enhancing the Potency of F508del Correction: A Multi-Layer Combinational Approach to Drug Discovery for Cystic Fibrosis. , 2013, Journal of pharmacology & clinical toxicology.

[14]  H. Dörr,et al.  Novel activating mutations of the calcium-sensing receptor: the calcilytic NPS-2143 mitigates excessive signal transduction of mutant receptors. , 2010, The Journal of clinical endocrinology and metabolism.

[15]  Richard I. Morimoto,et al.  Adapting Proteostasis for Disease Intervention , 2008, Science.

[16]  M. Reich,et al.  5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. , 1998, Journal of medicinal chemistry.

[17]  N. Leidenheimer,et al.  Pharmacological chaperoning: a primer on mechanism and pharmacology. , 2014, Pharmacological research.

[18]  W. Gahl,et al.  Lysosomal storage diseases , 2016, Translational science of rare diseases.

[19]  C. Deber,et al.  Misfolding of the cystic fibrosis transmembrane conductance regulator and disease. , 2008, Biochemistry.

[20]  S. Brothers,et al.  Pharmacologic Rescue of Conformationally‐Defective Proteins: Implications for the Treatment of Human Disease , 2004, Traffic.

[21]  K. Hofbauer,et al.  Peripheral Administration of a Melanocortin 4-Receptor Inverse Agonist Prevents Loss of Lean Body Mass in Tumor-Bearing Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.

[22]  D. Clarke,et al.  Chemical and pharmacological chaperones as new therapeutic agents , 2007, Expert Reviews in Molecular Medicine.

[23]  S. Angers,et al.  Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. , 2000, The Journal of clinical investigation.

[24]  N. Dokholyan,et al.  Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis , 2014, Science Translational Medicine.

[25]  Jeffrey L Brodsky,et al.  The Recognition and Retrotranslocation of Misfolded Proteins from the Endoplasmic Reticulum , 2008, Traffic.

[26]  J. Deng,et al.  Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy , 2013, Proceedings of the National Academy of Sciences.

[27]  David Y. Thomas,et al.  Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines , 2013, Orphanet Journal of Rare Diseases.

[28]  Robert J. Desnick,et al.  Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. , 2001, The New England journal of medicine.

[29]  S. Kaushal,et al.  Retinoids Assist the Cellular Folding of the Autosomal Dominant Retinitis Pigmentosa Opsin Mutant P23H* , 2004, Journal of Biological Chemistry.

[30]  P. Conn,et al.  Salt bridge integrates GPCR activation with protein trafficking , 2010, Proceedings of the National Academy of Sciences.

[31]  M. Horie,et al.  Novel intracellular transport-refractory mutations in KCNH2 identified in patients with symptomatic long QT syndrome. , 2017, Journal of cardiology.

[32]  D. Wolf,et al.  ER Degradation of a Misfolded Luminal Protein by the Cytosolic Ubiquitin-Proteasome Pathway , 1996, Science.

[33]  A. Cooper,et al.  Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death. , 2004, Molecular cell.

[34]  P. Conn,et al.  Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease , 2009, Molecular and Cellular Endocrinology.

[35]  D. Bichet,et al.  Pharmacological chaperone action on G-protein-coupled receptors. , 2004, Current opinion in pharmacology.

[36]  Hye Kyong Kweon,et al.  Glycosylation Quality Control by the Golgi Structure. , 2016, Journal of molecular biology.

[37]  N. Johnson,et al.  Transmembrane domain quality control systems operate at the endoplasmic reticulum and Golgi apparatus , 2017, PloS one.

[38]  J. Flanagan,et al.  Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. , 2011, Assay and drug development technologies.

[39]  J. Greer,et al.  Structure-Activity Relations of Successful Pharmacologic Chaperones for Rescue of Naturally Occurring and Manufactured Mutants of the Gonadotropin-Releasing Hormone Receptor , 2003, Journal of Pharmacology and Experimental Therapeutics.

[40]  P. Conn,et al.  G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo , 2007, Pharmacological Reviews.

[41]  E. Zaklyazminskaya,et al.  Cardiac channelopathies: genetic and molecular mechanisms. , 2013, Gene.

[42]  J. Caramelo,et al.  Getting In and Out from Calnexin/Calreticulin Cycles* , 2008, Journal of Biological Chemistry.

[43]  Satoshi Omura,et al.  Degradation of CFTR by the ubiquitin-proteasome pathway , 1995, Cell.

[44]  Xiao-Jing Di,et al.  Using pharmacological chaperones to restore proteostasis. , 2014, Pharmacological research.

[45]  C. McArdle,et al.  Rescue of expression and signaling of human luteinizing hormone G protein-coupled receptor mutants with an allosterically binding small-molecule agonist , 2011, Proceedings of the National Academy of Sciences.

[46]  C. January,et al.  Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel. , 1999, Circulation.

[47]  J. M. Sauder,et al.  Impact of the ΔF508 Mutation in First Nucleotide-binding Domain of Human Cystic Fibrosis Transmembrane Conductance Regulator on Domain Folding and Structure* , 2005, Journal of Biological Chemistry.

[48]  A. Rolfs,et al.  Fabry disease: a review of current management strategies. , 2010, QJM : monthly journal of the Association of Physicians.

[49]  P. Conn,et al.  Molecular basis of hypogonadotropic hypogonadism: restoration of mutant (E(90)K) GnRH receptor function by a deletion at a distant site. , 2002, The Journal of clinical endocrinology and metabolism.

[50]  J. Buchner,et al.  The heat shock response: life on the verge of death. , 2010, Molecular cell.

[51]  V. Hruby,et al.  Contribution of the Conserved Amino Acids of the Melanocortin-4 Receptor in d-[Nle4,Phe7]-α-Melanocyte-stimulating Hormone Binding and Signaling* , 2007, Journal of Biological Chemistry.

[52]  A. Minton,et al.  Protein aggregation in crowded environments , 2006, Biological chemistry.

[53]  D. Bichet,et al.  Nephrogenic diabetes insipidus. , 2001, Annual review of physiology.

[54]  Y. Tao Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity , 2005, Molecular and Cellular Endocrinology.

[55]  J. Riordan,et al.  Multiple proteolytic systems, including the proteasome, contribute to CFTR processing , 1995, Cell.

[56]  P. Conn,et al.  Misrouted cell surface GnRH receptors as a disease aetiology for congenital isolated hypogonadotrophic hypogonadism. , 2004, Human reproduction update.

[57]  F. Hartl,et al.  Converging concepts of protein folding in vitro and in vivo , 2009, Nature Structural &Molecular Biology.

[58]  R. Fenton,et al.  Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. , 2013, Endocrine reviews.

[59]  P. Arvan,et al.  Secretory Pathway Quality Control Operating in Golgi, Plasmalemmal, and Endosomal Systems , 2002, Traffic.

[60]  J. Robben,et al.  Potential of Nonpeptide (Ant)agonists to Rescue Vasopressin V2 Receptor Mutants for the Treatment of X‐linked Nephrogenic Diabetes Insipidus , 2010, Journal of neuroendocrinology.

[61]  Patrick Kim Chiaw,et al.  Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy. , 2011, Essays in biochemistry.

[62]  A. Cooper,et al.  ERADicate ER stress or die trying. , 2007, Antioxidants & redox signaling.

[63]  Martin L. Duennwald,et al.  Small Heat Shock Proteins Potentiate Amyloid Dissolution by Protein Disaggregases from Yeast and Humans , 2012, PLoS biology.

[64]  David B. Williams Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic reticulum , 2006, Journal of Cell Science.

[65]  H. Schneider Limitations and Extensions of the Lock-and-Key Principle: Differences between Gas State, Solution and Solid State Structures , 2015, International journal of molecular sciences.

[66]  D. Ejima,et al.  Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs. , 2006, Biochimica et biophysica acta.

[67]  C. January,et al.  Molecular pathogenesis of long QT syndrome type 2 , 2016, Journal of arrhythmia.

[68]  Shi-Qing Cai,et al.  Tetrameric Assembly of K+ Channels Requires ER-Located Chaperone Proteins. , 2017, Molecular cell.

[69]  Michel Bouvier,et al.  Pharmacological chaperones: potential treatment for conformational diseases , 2004, Trends in Endocrinology & Metabolism.

[70]  Vasilis Vasiliou,et al.  Human ATP-binding cassette (ABC) transporter family , 2009, Human Genomics.

[71]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[72]  Jonathan W. Yewdell,et al.  Rapid degradation of a large fraction of newly synthesized proteins by proteasomes , 2000, Nature.

[73]  J. Clancy,et al.  Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. , 2010, The New England journal of medicine.

[74]  J. Meldolesi,et al.  BiP, a Major Chaperone Protein of the Endoplasmic Reticulum Lumen, Plays a Direct and Important Role in the Storage of the Rapidly Exchanging Pool of Ca2+ * , 1997, The Journal of Biological Chemistry.

[75]  Tommer Ravid,et al.  Diversity of degradation signals in the ubiquitin–proteasome system , 2008, Nature Reviews Molecular Cell Biology.

[76]  Rahul S. Rajan,et al.  A Rhodopsin Mutant Linked to Autosomal Dominant Retinitis Pigmentosa Is Prone to Aggregate and Interacts with the Ubiquitin Proteasome System* , 2002, The Journal of Biological Chemistry.

[77]  E. Ingenito,et al.  Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del , 2017, The New England journal of medicine.

[78]  C. January,et al.  Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism , 2006, Circulation.

[79]  G. Milligan,et al.  Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists , 2009, Proceedings of the National Academy of Sciences.

[80]  S. Brothers,et al.  Human loss-of-function gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum: molecular basis of the dominant-negative effect. , 2004, Molecular endocrinology.

[81]  D. Cyr,et al.  The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation , 2000, Nature Cell Biology.

[82]  John R Yates,et al.  Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. , 2010, Nature chemical biology.

[83]  N. Bradbury,et al.  Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator and Drugs: Insights from Cellular Trafficking. , 2018, Handbook of experimental pharmacology.

[84]  M. Welsh,et al.  Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis , 1993, Cell.

[85]  K. Menon,et al.  Evidence that palmitoylation of carboxyl terminus cysteine residues of the human luteinizing hormone receptor regulates postendocytic processing. , 2005, Molecular endocrinology.

[86]  Andreas Bracher,et al.  Molecular chaperones in protein folding and proteostasis , 2011, Nature.

[87]  G. Breitwieser,et al.  Rescue of Calcium-sensing Receptor Mutants by Allosteric Modulators Reveals a Conformational Checkpoint in Receptor Biogenesis* , 2007, Journal of Biological Chemistry.

[88]  Y. Tao Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications. , 2006, Pharmacology & therapeutics.

[89]  C. Zuker,et al.  Defective intracellular transport is the molecular basis of rhodopsin-dependent dominant retinal degeneration. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[90]  J. Yuan,et al.  Mutant hERG channel traffic jam. Focus on "Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum". , 2013, American journal of physiology. Cell physiology.

[91]  F. Hartl,et al.  The role of molecular chaperones in protein folding , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[92]  P. Conn,et al.  Intracellular Trafficking of G Protein-Coupled Receptors to the Plasma Membrane in Health and Disease , 2014 .

[93]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[94]  M. Pringle,et al.  Folding of a single domain protein entering the endoplasmic reticulum precedes disulfide formation , 2017, The Journal of Biological Chemistry.

[95]  N. Pfanner,et al.  Protein unfolding by mitochondria , 2000, EMBO reports.

[96]  Ping Li,et al.  Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. , 2004, Journal of medicinal chemistry.

[97]  P. Conn,et al.  Receptor-misrouting: an unexpectedly prevalent and rescuable etiology in gonadotropin-releasing hormone receptor-mediated hypogonadotropic hypogonadism. , 2002, The Journal of clinical endocrinology and metabolism.

[98]  C. January,et al.  Correction of Defective Protein Trafficking of a Mutant HERG Potassium Channel in Human Long QT Syndrome , 1999, The Journal of Biological Chemistry.

[99]  Chris Fellner,et al.  CFTR Modulators for the Treatment of Cystic Fibrosis. , 2014, P & T : a peer-reviewed journal for formulary management.

[100]  S. Lindquist,et al.  Hsp104, Hsp70, and Hsp40 A Novel Chaperone System that Rescues Previously Aggregated Proteins , 1998, Cell.

[101]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[102]  Michel Bouvier,et al.  Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. , 2005, Journal of the American Society of Nephrology : JASN.

[103]  Canhui Li,et al.  A Small-Molecule Modulator Interacts Directly with ΔPhe508-CFTR to Modify Its ATPase Activity and Conformational Stability , 2009, Molecular Pharmacology.

[104]  H. Kampinga,et al.  The HSP70 chaperone machinery: J proteins as drivers of functional specificity , 2010, Nature Reviews Molecular Cell Biology.

[105]  T. Spicer,et al.  Assay strategies for identification of therapeutic leads that target protein trafficking. , 2015, Trends in pharmacological sciences.

[106]  G. Robertson,et al.  HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.

[107]  P. Harmatz Enzyme Replacement Therapies and Immunogenicity in Lysosomal Storage Diseases: Is There a Pattern? , 2015, Clinical therapeutics.

[108]  A. Cavanaugh,et al.  Pharmacochaperone-mediated rescue of calcium-sensing receptor loss-of-function mutants. , 2009, Molecular endocrinology.

[109]  P. Deen,et al.  Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. , 2007, American journal of physiology. Renal physiology.

[110]  K. Loeb,et al.  Multiple mutations and cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[111]  R. Kaufman,et al.  The impact of the unfolded protein response on human disease , 2012, The Journal of cell biology.

[112]  P. Conn,et al.  Drug development and the cellular quality control system. , 2009, Trends in pharmacological sciences.

[113]  A. Cavanaugh,et al.  Calcium-sensing Receptor Biosynthesis Includes a Cotranslational Conformational Checkpoint and Endoplasmic Reticulum Retention* , 2010, The Journal of Biological Chemistry.

[114]  L. Tsui,et al.  Erratum: Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA , 1989, Science.

[115]  C. Timossi,et al.  Structure-function relationship of follicle-stimulating hormone and its receptor. , 1998, Human reproduction update.

[116]  D. Ron,et al.  Conformational disease , 2000, Nature Cell Biology.

[117]  J. Sambrook,et al.  Protein folding in the cell , 1992, Nature.

[118]  S. Ishii,et al.  Pharmacological chaperone therapy for Fabry disease , 2012, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[119]  C. Timossi,et al.  Biochemical and functional aspects of gonadotrophin-releasing hormone and gonadotrophins. , 2000, Reproductive biomedicine online.

[120]  P. Conn,et al.  Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors. , 2011, Advances in pharmacology.

[121]  Satoshi Ishii,et al.  Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor , 1999, Nature Medicine.

[122]  P. Michael Conn,et al.  Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs , 2010, Trends in Endocrinology & Metabolism.

[123]  Y. Tao The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. , 2010, Endocrine reviews.

[124]  Christopher M Dobson,et al.  Principles of protein folding, misfolding and aggregation. , 2004, Seminars in cell & developmental biology.

[125]  P. Compain,et al.  Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease. , 2006, Bioorganic & medicinal chemistry.

[126]  Shuxia Zhao,et al.  The Binding Site for Channel Blockers That Rescue Misprocessed Human Long QT Syndrome Type 2 ether-a-gogo-related Gene (HERG) Mutations* , 2002, The Journal of Biological Chemistry.

[127]  Y. Tao,et al.  A Small Molecule Agonist THIQ as a Novel Pharmacoperone for Intracellularly Retained Melanocortin-4 Receptor Mutants , 2014, International journal of biological sciences.

[128]  P. Conn,et al.  Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function , 2014, Molecular and Cellular Endocrinology.

[129]  Kai Du,et al.  The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR , 2005, Nature Structural &Molecular Biology.

[130]  Hong Yu Ren,et al.  VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1 , 2013, Molecular biology of the cell.

[131]  David Y. Thomas,et al.  Novel pharmacological strategies to treat cystic fibrosis. , 2013, Trends in pharmacological sciences.

[132]  Zayd M. Khaliq,et al.  A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism , 2016, The Journal of Neuroscience.

[133]  A. Nakano,et al.  Membrane protein retrieval from the Golgi apparatus to the endoplasmic reticulum (ER): characterization of the RER1 gene product as a component involved in ER localization of Sec12p. , 1995, Molecular biology of the cell.

[134]  Ying Wang,et al.  Correctors Promote Maturation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-processing Mutants by Binding to the Protein* , 2007, Journal of Biological Chemistry.

[135]  Jean A Castillo-Badillo,et al.  Role of Cysteine Residues in the Carboxyl-Terminus of the Follicle-Stimulating Hormone Receptor in Intracellular Traffic and Postendocytic Processing , 2016, Front. Cell Dev. Biol..

[136]  M. Welsh,et al.  Structure and function of the CFTR chloride channel. , 1999, Physiological reviews.

[137]  P. Deen,et al.  Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. , 2006, American journal of physiology. Renal physiology.

[138]  B. Baldo,et al.  Enzymes Approved for Human Therapy: Indications, Mechanisms and Adverse Effects , 2015, BioDrugs.

[139]  Ying Wang,et al.  Specific Rescue of Cystic Fibrosis Transmembrane Conductance Regulator Processing Mutants Using Pharmacological Chaperones , 2006, Molecular Pharmacology.

[140]  D. Bichet,et al.  Pharmacological chaperones: a new twist on receptor folding. , 2000, Trends in pharmacological sciences.

[141]  T. Rush,et al.  Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: the GnRH receptor. , 2009, Molecular endocrinology.

[142]  B. Papsin,et al.  Misfolding diverts CFTR from recycling to degradation , 2004, The Journal of cell biology.

[143]  Ari Helenius,et al.  Quality control in the endoplasmic reticulum , 2003, Nature Reviews Molecular Cell Biology.

[144]  F. Hartl,et al.  Molecular Chaperones in the Cytosol: from Nascent Chain to Folded Protein , 2002, Science.

[145]  P. Conn,et al.  In vitro coexpression and pharmacological rescue of mutant gonadotropin-releasing hormone receptors causing hypogonadotropic hypogonadism in humans expressing compound heterozygous alleles. , 2005, The Journal of clinical endocrinology and metabolism.

[146]  C. January,et al.  HERG Channel Dysfunction in Human Long QT Syndrome , 1998, The Journal of Biological Chemistry.

[147]  R. Kaufman,et al.  A trip to the ER: coping with stress. , 2004, Trends in cell biology.

[148]  A. Aiuti,et al.  Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I , 2017, Journal of Inherited Metabolic Disease.

[149]  Y. Tao,et al.  Pharmacological chaperones for the misfolded melanocortin-4 receptor associated with human obesity. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[150]  Kirby Ef,et al.  Enhancing the Potency of F508del Correction: A Multi-Layer Combinational Approach to Drug Discovery for Cystic Fibrosis. , 2013 .

[151]  Jason C. Young,et al.  Pathways of chaperone-mediated protein folding in the cytosol , 2004, Nature Reviews Molecular Cell Biology.

[152]  Jonathan Weissman,et al.  Molecular Chaperones and Protein Quality Control , 2006, Cell.

[153]  P. Conn,et al.  Chaperoning G protein-coupled receptors: from cell biology to therapeutics. , 2014, Endocrine reviews.

[154]  C. Bear,et al.  Probing Conformational Rescue Induced by a Chemical Corrector of F508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutant* , 2011, The Journal of Biological Chemistry.

[155]  V. Hruby,et al.  Contribution of the conserved amino acids of the melanocortin-4 receptor in [corrected] [Nle4,D-Phe7]-alpha-melanocyte-stimulating [corrected] hormone binding and signaling. , 2007, The Journal of biological chemistry.

[156]  J. Stirnemann,et al.  A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments , 2017, International journal of molecular sciences.

[157]  A. Rzhetsky,et al.  The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.

[158]  P. Deen,et al.  Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism. , 2005, Molecular biology of the cell.

[159]  David Y. Thomas,et al.  Lectin control of protein folding and sorting in the secretory pathway. , 2003, Trends in biochemical sciences.

[160]  G. Durand,et al.  Normal testicular function without detectable follicle-stimulating hormone. A novel mutation in the follicle-stimulating hormone receptor gene leading to apparent constitutive activity and impaired agonist-induced desensitization and internalization , 2012, Molecular and Cellular Endocrinology.

[161]  D. Krainc,et al.  α-Synuclein–induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models , 2016, Proceedings of the National Academy of Sciences.

[162]  E. Abel,et al.  Lipids, lysosomes, and autophagy , 2016, Journal of Lipid Research.

[163]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[164]  Daniel C Bartos,et al.  Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum. , 2013, American journal of physiology. Cell physiology.

[165]  Zhen‐Chuan Fan,et al.  Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients , 2009, Journal of cellular and molecular medicine.

[166]  T. Gudermann,et al.  Mutations of the human thyrotropin receptor gene causing thyroid hypoplasia and persistent congenital hypothyroidism. , 1997, The Journal of clinical endocrinology and metabolism.

[167]  Christine E. Bear,et al.  A Chemical Corrector Modifies the Channel Function of F508del-CFTR , 2010, Molecular Pharmacology.

[168]  Guillaume Godin,et al.  Design and Synthesis of Highly Potent and Selective Pharmacological Chaperones for the Treatment of Gaucher's disease , 2006, Chembiochem : a European journal of chemical biology.

[169]  G. Lukács,et al.  Protein quality control at the plasma membrane. , 2011, Current opinion in cell biology.

[170]  P. H. Cameron,et al.  The endoplasmic reticulum: integration of protein folding, quality control, signaling and degradation. , 2001, Current opinion in structural biology.

[171]  Marcel Hibert,et al.  Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. , 2009, Journal of the American Society of Nephrology : JASN.

[172]  F. Ratjen Cystic fibrosis: pathogenesis and future treatment strategies. , 2009, Respiratory care.

[173]  P. Conn,et al.  Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases. , 2018, Physiological reviews.

[174]  S. Persaud,et al.  Cellular Endocrinology in Health and Disease , 2014 .

[175]  R. Brady,et al.  Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function , 2011, Proceedings of the National Academy of Sciences.

[176]  F. Pinet,et al.  Functional Characterization of Three Mutations of the Endothelin B Receptor Gene in Patients With Hirschsprung’s Disease: Evidence for Selective Loss of Gi Coupling , 2001, Molecular medicine.

[177]  A. Wilde,et al.  Inherited ion channel diseases: a brief review. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[178]  B. Wiesner,et al.  Pharmacochaperones Post-translationally Enhance Cell Surface Expression by Increasing Conformational Stability of Wild-type and Mutant Vasopressin V2 Receptors* , 2004, Journal of Biological Chemistry.

[179]  J. Greer,et al.  Refolding of misfolded mutant GPCR: Post-translational pharmacoperone action in vitro , 2007, Molecular and Cellular Endocrinology.

[180]  A. Helenius,et al.  ER quality control: towards an understanding at the molecular level. , 2001, Current opinion in cell biology.

[181]  S. Garland Are GPCRs Still a Source of New Targets? , 2013, Journal of biomolecular screening.

[182]  A. Helenius,et al.  Roles of N-linked glycans in the endoplasmic reticulum. , 2004, Annual review of biochemistry.

[183]  A. Verkman,et al.  Cystic fibrosis transmembrane regulator correctors and potentiators. , 2013, Cold Spring Harbor perspectives in medicine.

[184]  D. Niu,et al.  Fabry disease: Review and experience during newborn screening. , 2017, Trends in cardiovascular medicine.

[185]  A. Parodi,et al.  Quality control and protein folding in the secretory pathway. , 2003, Annual review of cell and developmental biology.

[186]  D. Krainc,et al.  Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons , 2016, The Journal of Neuroscience.

[187]  A. Cooper,et al.  Misfolded proteins traffic from the endoplasmic reticulum (ER) due to ER export signals. , 2006, Molecular biology of the cell.

[188]  A. J. Parodi,et al.  Role of N-oligosaccharide endoplasmic reticulum processing reactions in glycoprotein folding and degradation. , 2000, The Biochemical journal.

[189]  S. Noel,et al.  Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives , 2016, Clinical pharmacology : advances and applications.

[190]  H. Katus,et al.  Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing. , 2003, Cardiovascular research.

[191]  Astha Koolwal,et al.  Ivacaftor: a novel mutation modulating drug. , 2014, Journal of clinical and diagnostic research : JCDR.

[192]  D. Clarke,et al.  Rescue of Folding Defects in ABC Transporters Using Pharmacological Chaperones , 2005, Journal of bioenergetics and biomembranes.

[193]  Rohan Dandage,et al.  Classification of chemical chaperones based on their effect on protein folding landscapes. , 2015, ACS chemical biology.

[194]  S. Weindling,et al.  Inherited arrhythmias: The cardiac channelopathies , 2015, Annals of pediatric cardiology.

[195]  M. Birnbaumer V2R structure and diabetes insipidus. , 2002, Receptors & channels.

[196]  Melanie A. Jones,et al.  Mechanisms of Pharmacological Rescue of Trafficking-defective hERG Mutant Channels in Human Long QT Syndrome* , 2006, Journal of Biological Chemistry.

[197]  C. January,et al.  Thapsigargin Selectively Rescues the Trafficking Defective LQT2 Channels G601S and F805C* , 2003, Journal of Biological Chemistry.